Ibio (IBIO) Stock: Gaining On Intellectual Property Update

0

Ibio Inc (NYSEMKT: IBIO) is having an overwhelmingly strong day in the market today, and for good reason. The company provided an intellectual property update early this morning that’s causing excitement among investors who are pushing the stock toward the top. As is nearly always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:58), IBIO is trading at $0.39 per share after a gain of $0.06 per share or 19.33% thus far today.





IBIO Gains On IP Update

As mentioned above, Ibio is having an overwhelmingly strong start to the trading session this morning after the company released a press release, updating investors with regard to recent patents and inventions. Here are the updates provided through the press release:




The company announced that on September 19, 2017, IBIO received a US patent with the serial number 9,765,349. The patent is titled “SYSTEM FOR EXPRESSION OF GENES IN PLANTS”. This patent adds further protection to the US patent number 9,551,001, which the company was granted early on in 2017.

The company also announced that it has further strengthened its intellectual property in the fibrosis arena with a patent obtained that covered the company’s idiopathic pulmonary fibrosis and systemic sclerosis product pipeline. The patent that was provided covered an invention made by Dr. Carol Feghali-Bostwick and colleagues and is titled “USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS”. THIS PATENT NUMBER IS 9,556,252. The patent was issued on January 31, 2017 and included claims covering the components of matter and method of use for endostatin-related peptides.

IBIO informed investors that it has obtained exclusive licenses to the patent above and related intellectual property that has been developed by Dr. Feghali-Bostwick and has entered into an ongoing collaboration agreement with Dr. Feghali-Bostwick’s current institution, the Medical University of South Carolina. This university has led further development and the invention of the potentially breakthrough biotherapeutic approach to fibrotic disease described by this family of patents.

Finally, IBIO said that it has received a Notice of Allowance for US serial number 14/366,071, which is entitled “INFLUENZA HEMAGGLUTININ ANTIBODIES, COMPOSITIONS AND RELATED METHODS”. Ultimately, this will further strengthen the company’s intellectual property in the vaccine and antibody category.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on IBIO. In particular, we’re interested in following the intellectual property updates surrounding and ongoing development of the company’s impressive pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









LEAVE A REPLY

Please enter your comment!
Please enter your name here